Neil Kumar, Chief Executive Officer and Director of BridgeBio Pharma, Inc. (NASDAQ:BBIO), filed a Form 4 on November 20, 2026, disclosing the sale of 54,980 shares of common stock across four transactions on November 18 and 19, 2026, executed under a Rule 10b5-1 sales plan.
Key Highlights
- Sales plan in place: All transactions were made pursuant to a Rule 10b5-1 sales plan adopted by Kumar on May 13, 2026.
- Direct account sales on Nov 18: Kumar disposed of 4,490 shares at a weighted average price of $76.9916 and 30,490 shares at a weighted average price of $77.8271, leaving 243,327 shares held directly.
- Trust account sales on Nov 18-19: 1,277 shares at $76.9915, 8,723 shares at $77.8269, 8,500 shares at $78.3503, and 1,500 shares at $79.293 were sold from the Kumar Haldea Family Irrevocable Trust, of which Kumar is a co-trustee.
- Post-transaction direct holdings: Following the reported transactions, Kumar directly held 243,327 shares of common stock.
- Indirect holdings remain substantial: Kumar indirectly holds 475,686 shares through the Kumar Haldea Family Irrevocable Trust, 750,000 shares through the NK 2026 GRAT, and 3,568,447 shares through the Kumar Haldea Revocable Trust.
- Beneficial ownership disclaimer: According to the filing, Kumar "disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein" for the trust-held shares.
BridgeBio CEO Kumar's Nov 18-19 Share Sales Under 10b5-1 Plan
According to the Form 4 filed on November 20, 2026, Neil Kumar, who serves as Chief Executive Officer and Director of BridgeBio Pharma, Inc. (NASDAQ:BBIO), sold a total of 54,980 shares of common stock on November 18 and 19, 2026. The filing indicates all transactions were carried out pursuant to a Rule 10b5-1 sales plan that Kumar adopted on May 13, 2026.
On November 18, 2026, Kumar sold 4,490 shares directly at a weighted average price of $76.9916 per share, with individual prices ranging from $76.43 to $77.42, and 30,490 shares directly at a weighted average price of $77.8271 per share, with individual prices ranging from $77.43 to $78.23. Additionally on November 18, 1,277 shares and 8,723 shares were sold from the Kumar Haldea Family Irrevocable Trust at weighted average prices of $76.9915 and $77.8269, respectively. On November 19, the trust sold a further 8,500 shares at a weighted average price of $78.3503 (range $78.00 to $78.98) and 1,500 shares at $79.293 (range $79.04 to $79.73).
After all reported transactions, Kumar's direct beneficial ownership stood at 243,327 shares. The filing also reports indirect holdings of 475,686 shares through the Kumar Haldea Family Irrevocable Trust, 750,000 shares through the NK 2026 GRAT (described as a grantor retained annuity trust of which Kumar is the sole trustee and sole annuitant), and 3,568,447 shares through the Kumar Haldea Revocable Trust. The filing notes Kumar disclaims beneficial ownership of shares held in the trusts except to the extent of any pecuniary interest.
What Was Disclosed
BridgeBio Pharma CEO Neil Kumar disclosed the sale of 54,980 shares of common stock on November 18 and 19, 2026, under a pre-existing Rule 10b5-1 plan, with weighted average prices ranging from $76.9915 to $79.293 per share across direct and trust-held accounts.




Please wait processing your request...